
NICE is not recommending Sanofi’s prostate cancer drug Jevtana due to its high cost and questions over its safety. In …

Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …

Janssen’s new advanced prostate cancer treatment Zytiga has been launched in the UK. Zytiga (abiraterone acetate) has been shown in …

Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …
Janssen’s prostate cancer treatment Zytiga has been recommended by Europe’s CHMP, paving the way for possible third quarter launch. The …
NICE’s next round of drug appraisals is set to include two new hepatitis C drugs – Merck Sharpe and Dohme’s …
Zytiga a new treatment for the most hard to treat cases of prostate cancer has been approved in the US. …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

